This is a research study to assess the effectiveness of a peer-led collaborative care model for integrating treatment for substance use and or mental health disorders into HIV care settings. Depending on whether or not participants enroll in this study, participants will be assigned randomly (by chance, like drawing a number from a hat) to one of two groups. In group 1, participants would receive usual clinical care. In group 2, participants would work with a peer-case manager who would help support participants to engage in substance use or mental health disorder care. Regardless of the group participants are in, participants will fill out a survey when first enrolled in the study, and then again 12 months later.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
405
Collaborative care (CC) is an evidence-based model of integrated mental health and substance use disorder care endorsed by the American Psychiatric Association for the integration of mental health and substance use disorder care into primary care settings. CC includes the following components: 1) A collaborative care team of multidisciplinary health care providers consisting of the primary physician, a care manager and a consulting psychiatrist, providing care in a coordinated fashion; 2) A population focus with the team working together to provide care and continuously measure and track health outcomes of a defined population of patients; 3) A measurement-guided approach with systematic use of disease specific patient reported outcome measures, such as symptom rating scales like the PHQ-9 to drive clinical decision making; and 4) Evidence-based practices with the team adapting scientifically proven treatments within an individual clinical context to achieve improved health outcomes.
Johns Hopkins Hospital
Baltimore, Maryland, United States
The Number of Participants with HIV Virologic Suppression
This is defined as a viral load \< 200 copies/ml
Time frame: Within a 3 month window of the 12 month follow-up (i.e. 3 months before or after the 12 month follow up)
Number of Participants with Retention in HIV Care
At least 2 medical visit dates, specifically for HIV care, that are at least 90 days apart
Time frame: Within 12 months of patient entrance into the study
Number of Participants Who Obtain Treatment for Mental Health and Substance Use Disorder
Receipt of evidence-based treatment for Mental Health and Substance Use Disorder, including medication and brief psychotherapy
Time frame: Within 12 month of patient entrance into the study
Number of Participants with Change in Severity of Mental Health and Substance Use Disorder
The following changes in Mental Health and Substance Use Disorder outcomes from baseline to 12 month follow up: Depression- 50% reduction in PHQ 9, Anxiety- 50% reduction in GAD 7, Bipolar Disorder- 50% reduction in Altman Mania Scores, PTSD- 50% reduction in PTSD Checklist 5, and Substance Use Disorder- 50% reduction in severity of dependence scale score
Time frame: Changes from baseline to 12 month follow up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.